Adjuvant taxane anthracycline therapy in HRHER2 BC with high RS values

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=WbIAXZBks5c

[Oncoinfo – Istantanee di Oncologia: seguici su http://oncoinfo.it] Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at SABCS 2024. We interviewed Nan Chen (Assistant professor of internal medicine - University of Chicago Medicine) about this analysis of the TAILORx trial during the congress in San Antonio.

#############################